Добірка наукової літератури з теми "Thyronine"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Thyronine".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Thyronine"
Witherspoon, L. R., A. S. el Shami, S. E. Shuler, H. Neely, R. Sonnemaker, S. S. Gilbert, and K. Alyea. "Chemically blocked analog assays for free thyronines. II. Use of equilibrium dialysis to optimize the displacement by chemical blockers of T4 analog and T3 analog from albumin while avoiding displacement of T4 and T3 from thyroxin-binding globulin." Clinical Chemistry 34, no. 1 (January 1, 1988): 17–23. http://dx.doi.org/10.1093/clinchem/34.1.17.
Повний текст джерелаZhu, Fan-Fan, and Li-Zhen Yang. "The Association Between the Levels of Thyroid Hormones and Peripheral Nerve Conduction in Patients with Type 2 Diabetes Mellitus." Experimental and Clinical Endocrinology & Diabetes 126, no. 08 (June 26, 2018): 493–504. http://dx.doi.org/10.1055/a-0635-0826.
Повний текст джерелаAceves, C., and R. Rojas-Huidobro. "Effect of suckling and adrenergic stimulation on peripheral deiodination in lactating rats: differential expression of type 1 deiodinase mRNA forms." Journal of Endocrinology 171, no. 3 (December 1, 2001): 533–40. http://dx.doi.org/10.1677/joe.0.1710533.
Повний текст джерелаValashek, I. E., P. M. Kochergin, E. M. Vinogradova, and L. I. Budanova. "Synthesis of 3,5-Diiodo-DL-thyronine." Pharmaceutical Chemistry Journal 29, no. 6 (June 1995): 418–19. http://dx.doi.org/10.1007/bf02220547.
Повний текст джерелаSHOJAEE-MORADIE, Fariba, Michelle P. Y. CHAN, Micayla A. TELFER, Dietrich BRANDENBURG, Erik SUNDERMANN, Heike ECKEY, Jens KLEINJUNG, Achim SCHÜTTLER, and Richard H. JONES. "Effect of thyroid hormone binding proteins on insulin receptor binding of B1-thyronine-insulin analogues." Biochemical Journal 381, no. 1 (June 22, 2004): 51–57. http://dx.doi.org/10.1042/bj20040177.
Повний текст джерелаOziol, L., P. Faure, N. Bertrand, and P. Chomard. "Inhibition of in vitro macrophage-induced low density lipoprotein oxidation by thyroid compounds." Journal of Endocrinology 177, no. 1 (April 1, 2003): 137–46. http://dx.doi.org/10.1677/joe.0.1770137.
Повний текст джерелаSegal, J., J. Hardiman, and S. H. Ingbar. "Stimulation of calcium-ATPase activity by 3,5,3′-tri-iodothyronine in rat thymocyte plasma membranes. A possible role in the modulation of cellular calcium concentration." Biochemical Journal 261, no. 3 (August 1, 1989): 749–54. http://dx.doi.org/10.1042/bj2610749.
Повний текст джерелаCoppola, Maria, Federica Cioffi, Maria Moreno, Fernando Goglia, and Elena Silvestri. "3,5-diiodo-L-thyronine: A Possible Pharmacological Agent?" Current Drug Delivery 13, no. 3 (May 20, 2016): 330–38. http://dx.doi.org/10.2174/1567201813666151123124340.
Повний текст джерелаLi, Shanshan, Bing Yang, Tomonori Kobayashi, Bingchen Yu, Jun Liu, and Lei Wang. "Genetically encoding thyronine for fluorescent detection of peroxynitrite." Bioorganic & Medicinal Chemistry 28, no. 18 (September 2020): 115665. http://dx.doi.org/10.1016/j.bmc.2020.115665.
Повний текст джерелаVALASHEK, I. E., P. M. KOCHERGIN, E. M. VINOGRADOVA, and L. I. BUDANOVA. "ChemInform Abstract: Synthesis of 3,5-Diiodo-DL-thyronine." ChemInform 27, no. 2 (August 12, 2010): no. http://dx.doi.org/10.1002/chin.199602253.
Повний текст джерелаДисертації з теми "Thyronine"
Dudley, Samuel C. "The Effects of Carboxyl-group Specific Modification and Triiodo-L-thyronine on Cardiac Sodium Channels." VCU Scholars Compass, 1991. http://scholarscompass.vcu.edu/etd/4527.
Повний текст джерелаBaas, Dominique. "Action de la 3,5,3' triiodo-l-thyronine au cours du developpement de l'oligodendrocyte : etude in vitro." Strasbourg 1, 1995. http://www.theses.fr/1995STR13200.
Повний текст джерелаLehmphul, Ina. "Zelluläre Wirkung, Wirkmechanismen und Nachweisverfahren von Schilddrüsenhormonen und ihren Metaboliten." Doctoral thesis, Humboldt-Universität zu Berlin, Lebenswissenschaftliche Fakultät, 2015. http://dx.doi.org/10.18452/17434.
Повний текст джерелаThyroid hormones (TH) regulate metabolism and energy metabolism. The TH‐metabolite (THM) 3,5‐T2 (3,5‐diiodo‐L‐thyronine) activates fat oxidation and mitochondrial respiration. The THM 3‐T1AM (3‐iodothyronamine) influences in addition glucoregulatory processes. THM may support reduction in body fat mass. It was the idea to establish, validate and apply an immunoassay to determine 3,5‐T2 in human serum. Using intact hepatocellular (HepG2) as well as pancreatic ß‐cells (MIN6) it should be tested if THM can modulate mitochondrial activity, resulting in increased cellular substrate usage (3,5‐T2) as well as decreased insulin secreation (3‐T1AM). The established immunoassay is sensitive, specific and detects precisely 3,5‐T2 in human serum. Hyper‐ and hypothyroidism shows similar 3,5‐T2 concentrations, although 3,5‐T2 accumulates in secondary thyroidal illness as well as in athyreotic patients under thyroxine‐supplementation. Using HepG2 cells, mitochondrial respiration was stimulated by 3,3‘,5‐triiodo‐L‐thyronine (T3), but 3,5‐T2 had no effect. Expression of TH‐transporters (THT) was low compared to murine hepatocytes. In contrast, MIN6 express THT comparable to murine Langerhans islets. 3‐T1AM is taken up by the cell, metabolized to 3‐iodothyroacetic acid (TA1) and following export. After 3‐T1AM application mitochondrial ATP‐production as well as glucose‐stimulated insulin secretion (GSIS) was reduced. 3,5‐T2 circulates in euthyroid individuals, is not involved in central regulation of TH‐axis, is produced extrathyroidally and low T3 values can be explained by increased 3,5‐T2. HepG2 was shown to be an inappropriate cellmodel, because THT are merely expressed, suggesting that 3,5‐T2 is not able to pass the plasma membrane, thereby preventing mitochondrial activation. In addition, it was shown in MIN6 cells, that GSIS is not exclusively regulated at the plasma membrane level via 3‐T1AM.
Hachi, Isma. "Etude structurale de biomarqueurs de neuropathologies : cas particulier de la protéine CRYM, une Cytosolic-3,3',5-triiodo-L-thyronine(T3)-Binding Protein." Grenoble, 2010. http://www.theses.fr/2010GRENV030.
Повний текст джерелаMy Ph. D. Work takes part of a larger project dedicated to the characterization of proteins newly involved into selective expression of certain mouse brain regions. This selective expression being potentially linked to neuronal degeneration associated with neurodegenerative diseases, the corresponding proteins are therefore potential biomarkers. A structural and physico-chemical study has been performed on about ten proteins including CRYM of mouse (mCRYM), which belongs to the Cytosolic-3,3',5-triiodo-L-thyronine(T3)-Binding Protein family since it regulates the concentration of free thyroid hormone, T3, in the cell. MCRYM also belongs to the µ-crystallin family and to the µ-crystallins/Ornithin Cyclodesaminases superfamily. Proteins displaying sequence homologies to these three families of proteins have generally different functions (enzymatic or structural), different tissue localisation and different physico-chemical properties. This diversity is due to the recruitment of genes of the crystalline superfamily to carry different metabolic functions while preserving the taxon-specific crystallins. I have managed to resolve the crystallographic structure of mCRYM in complex with NADP(H) and the thyroid hormone, T3, to 1. 75 Å resolution. MCRYM is a very interesting evolution specimen as it belongs to a different family of proteins. However, no enzymatic function has ever been demonstrated for mCRYM. Its structural and thermodynamical characterization has revealed similitudes and divergences with the enzymatic homologues of CRYM and has allowed us to make hypothesis relative to its molecular evolution. These results raise new questions concerning the physiological role of mammalian CRYM: is CRYM an enzyme or a structural protein? How does the NADPH/NADP+ redox couple regulates the genomic and/or non genomic action of the T3 hormone? Is the T3 hormone the only physiological ligand of CRYM in the brain?
Hachi, Isma. "Etude structurale de biomarqueurs de neuropathologies : Cas particulier de la protéine CRYM, une Cytosolic-3,3',5-triiodo-L-thyronine(T3)-Binding Protein." Phd thesis, Université de Grenoble, 2010. http://tel.archives-ouvertes.fr/tel-00718112.
Повний текст джерелаGonzales, Christopher R. "3,3′,5′-triido-L-thyronine alters protein kinase B, phosphotase and tensin homolog and connective tissue growth factor expression in human dermal fibroblasts." Thesis, Boston University, 2012. https://hdl.handle.net/2144/12397.
Повний текст джерелаCutaneous tissue repair is complex and involves a variety of growth factors to regulate a balance of regeneration and fibrosis during healing. This process is divided into three sequential and overlapping phases: the inflammatory phase, the proliferative phase, and the remodeling phase. Fibroblasts are crucial during this process in that they help initiate inflammatory activity, deposit extracellular matrix proteins for granulation tissue and deconstruct granulation tissue to make way for mature scar formation. Previous studies on the effects of 3,3',5'-triiodo-L-thyronine (T3) on skin have revealed that healing tissue responds to T3 by accelerating skin cell proliferation and migration. These findings indicate that T3 offers potential as a therapeutic drug for individuals with extensive cutaneous damage, chronic skin maladies or retarded wound healing. The mechanisms underlying these changes are not clearly understood, however, elucidation of changes in protein expression patterns should be evaluated to appropriately judge the therapeutic potential of T3. This study aims to characterize T3 dose responsive expression of protein kinase B, phosphatase and tensin homolog, connective tissue growth factor and wnt5a. Western blot analysis and immunodetection revealed that wnt5a is not expressed in human dermal fibroblasts. Protein kinase B did not vary significantly with T3 concentration ranging from 1.0 nM-1.0 1µM, F(4,5)= 1.93, p > 0.05, nor did connective tissue growth factor, F(4,5) = 2.16, p > 0.05. In contrast, phosphatase and tensin homolog showed a statistically significant change in expression, F(4, 15) = 4.67, p less than 0.05. The results presented here provide insight into protein pathways and growth factors through which thyroid hormone produces its effects on the various cells of the integument and suggests that phosphatase and tensin homolog (PTEN) expression levels are responsive to varying concentrations of T3. Future studies should further evaluate the role of T3 on its various targets as a therapeutic option for skin disorders.
Serrar, Mostafa. "Effets croisés des régimes enrichis en stérols ou en acides biliaires et du traitement par la 3, 5,3’triiodo-L-thyronine (t3) sur les activités des enzymes microsomales hépatiques responsables du métabolisme des xénobiotiques chez le rat." Dijon, 1987. http://www.theses.fr/1987DIJOS043.
Повний текст джерелаNicolas, Patrick. "Modulation pharmacologique des activités thyronine-désiodases, enzymes de monodésiodation des hormones thyroi͏̈diennes : application : la 5'-désiodase de type II (5D'II) et la triiodothyronine (T) dans la correction des troubles de l'humeur." Paris 13, 1996. http://www.theses.fr/1996PA1300T1.
Повний текст джерелаPiehl, Susanne. "The roles of deiodinases in thyronamine biology." Doctoral thesis, Humboldt-Universität zu Berlin, Mathematisch-Naturwissenschaftliche Fakultät I, 2008. http://dx.doi.org/10.18452/15795.
Повний текст джерела3-iodothyronamine (3-T1AM) and thyronamine (T0AM) are novel endogenous signaling molecules that exhibit great structural similarity to thyroid hormones but apparently antagonize classical thyroid hormone (T3) actions. The present study investigated whether thyronamines (TAMs) are substrates of three Dio isozymes (Dio1, Dio2 and Dio3). TAMs were incubated with isozyme specific Dio preparations. Deiodination products were analyzed using a newly established method applying liquid chromatography and tandem mass spectrometry (LC-MS/MS). Phenolic ring deiodinations of 3,3’,5’-triiodothyronamine, 3’,5’- and 3,3’-diiodothyronamine as well as tyrosyl ring deiodinations of 3,5,3’-triiodothyronamine and 3,5-diiodothyronamine were observed with preparations containing Dio1. Preparations of Dio2 also deiodinated 3,3’,5’-triiodothyronamine and 3’,5’-diiodothyronamine at the phenolic rings. All TAMs with tyrosyl ring iodine atoms were deiodinated by Dio3 containing preparations. In functional competition assays, the newly identified TAM substrates inhibited an established iodothyronine deiodination reaction. By contrast, TAMs which had been excluded as Dio substrates in LC-MS/MS experiments, failed to show any effect in the competition assays, thus verifying the former results. In summary, all three Dio isozymes catalyzed TAM deiodination reactions with each isozyme exhibiting a unique substrate specificity. These data support a role for Dio isozymes in TAM biosynthesis and contribute to confining the biosynthetic pathways of 3-T1AM and T0AM. Furthermore, they provide new insights into the structural requirements for Dio substrates in general since TAMs represent the only endogenous Dio substrates described, so far, which possess a positively charged tyrosyl ring side chain.
Hanna, Atef Nagib. "Inhibition of low density lipoprotein oxidation by thyronines, probucol, ascorbate and ACI-reductones /." The Ohio State University, 1993. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487843314697076.
Повний текст джерелаЧастини книг з теми "Thyronine"
Lissitzky, S., and S. Bouchilloux. "Enzymic Aspects of Thyronine Metabolism and its Iodinated Derivatives." In Ciba Foundation Symposium - Regulation and Mode of Action of Thyroid Hormones (Colloquia on Endocrinology, Vol. 10), 135–55. Chichester, UK: John Wiley & Sons, Ltd., 2008. http://dx.doi.org/10.1002/9780470719022.ch10.
Повний текст джерелаRoche, Jean, Raymond Michel, and Pierre Jouan. "On the Presence of 3:5:3′-Triiodothyro-Acetic Acid and 3:3′-Diiodothyronine in Rat Muscle and Kidney after Administration of 3:5:3′-Triiodo-L-Thyronine." In Ciba Foundation Symposium - Regulation and Mode of Action of Thyroid Hormones (Colloquia on Endocrinology, Vol. 10), 168–81. Chichester, UK: John Wiley & Sons, Ltd., 2008. http://dx.doi.org/10.1002/9780470719022.ch12.
Повний текст джерела"Thyronine (3p-[p(p-hydroxyphenoxy)-phenyl]-l-alanine)." In Encyclopedia of Genetics, Genomics, Proteomics and Informatics, 1966. Dordrecht: Springer Netherlands, 2008. http://dx.doi.org/10.1007/978-1-4020-6754-9_16982.
Повний текст джерелаТези доповідей конференцій з теми "Thyronine"
Lei, Jianxun, Douglas O. Wangensteen, and David H. Ingbar. "3,3',5-Triiodo-L-Thyronine (T3) Enhances Adult Alveolar Type II Cell Survival Under Hyperoxia." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a1965.
Повний текст джерелаЗвіти організацій з теми "Thyronine"
Wahl, Troy. Developing Thyronamine Analog Pharmaceuticals Targeting TAAR1 to Treat Methamphetamine Addiction. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.1109.
Повний текст джерела